I’d buy these 5 FTSE 100 stocks in 2021 to achieve financial freedom

I believe the best way to achieve financial freedom is to build a balanced portfolio of FTSE 100 stocks offering income and growth in 2021 and beyond.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

As the year draws to a close, I’m drawing up a hit list of top FTSE 100 stocks to build my wealth in 2021 and beyond. This year has been tough for investors, but Covid-19 vaccines now promise a brighter future.

There are still plenty of bargain FTSE 100 stocks out there. I think these three should give me the dividend income and share price I’m after to achieve financial freedom and retire at a time of my choosing.

My first pick is FTSE 100 ‘big pharma’ stock GlaxoSmithKline (LSE: GSK). AstraZeneca has dominated the headlines lately, following its Oxford vaccine breakthrough, but Glaxo looks the superior dividend stock today, I feel.

Today, Glaxo yields 5.77%, and unlike many FTSE 100 stocks has maintained shareholder payouts throughout the pandemic. Chief executive Emma Walmsley may have held the dividend at 80p for five years, now, but I’m not complaining given that yield. 

The Glaxo share price has fallen by around a fifth in recent months and I reckon this gives me a great buying opportunity. Today, it trades at just 11.1 times earnings. Believe me, that is cheap for Glaxo. Usually I would consider myself lucky to buy it at 15 times. 

I’d buy these FTSE 100 stocks in 2021

My next FTSE 100 stock pick is more controversial. Oil giant BP (LSE: BP) is facing an existential threat from the rise of renewables, and the war on climate change. Chief executive Bernard Looney is desperately trying to repurpose BP for the net carbon zero world, and there is no guarantee he will win.

Yet I still believe BP can generate healthy income and growth from its legacy fossil fuel business, while switching to greener forms of energy. In the interim, BP offers a whopping forecast yield of 8.4%, despite halving its dividend in August. 

The BP share price is climbing right now and could rebound further as the world starts travelling again. Brent crude is nudging $50 a barrel and the higher it climbs the better this FTSE 100 stock will perform.

I’ll be crying financial freedom

Asset manager and insurer Legal & General Group (LSE: LGEN) has maintained its income throughout the pandemic, holding its nerve even as rival Aviva slashed its payout. Today, it offers investors a juicy forward yield of 6.9%, covered 1.6 times by earnings.

The L&G share price has jumped almost 40% in the last month, which I’m glad to see, given that I have been tipping the stock for years. So it’s not as cheap as it was, but this FTSE 100 stock still looks nicely priced, trading at 8.63 times earnings.

Legal & General has shown its resilience through what should have been a tough year for asset managers. The combination of a low entry price, solid long-term prospects and generous dividend policy makes it a top retirement stock for my portfolio. I’d buy these three in 2021 and move a step closer to achieving financial freedom.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »